Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;91(3):421-430.
doi: 10.1016/j.jaad.2023.07.1052. Epub 2024 Apr 6.

Extramammary Paget disease. Part II. Evidence-based approach to management

Affiliations
Review

Extramammary Paget disease. Part II. Evidence-based approach to management

Rohan R Shah et al. J Am Acad Dermatol. 2024 Sep.

Abstract

Extramammary Paget disease is a rare cutaneous malignancy that most commonly affects the genitals, perianal area, and axilla of elderly patients. Delays in care often lead to high levels of disease burden for patients. Thus, evidence-based recommendations are paramount in mitigating morbidity and mortality for this unique patient population. This 2-part continuing medical education series provides a complete picture of extramammary Paget disease. Part 2 of this continuing medical education series focuses on the complex management of extramammary Paget disease including surgical and noninvasive therapies, as well as novel approaches for advanced disease.

Keywords: Extramammary Paget disease; Mohs micrographic surgery; imiquimod; margin control; photodynamic therapy; radiation therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Rossi has no relevant conflicts of interest related to this article but has received grant funding from The Skin Cancer Foundation and the A. Ward Ford Memorial Grant, served on advisory board, as a consultant, given educational presentations for Almirall, Allergan Inc, Galderma Inc, Evolus Inc, Elekta, Biofrontera (Quantia), Merz Inc, Dynamed, Skinuvia, Perf-Action, Cutera, and LAM therapeutics, and holds equity in DAR companies. Dr Funt has received research support from AstraZenecaAstraZeneca, GenentechGenentech/RocheRoche, and Decibel Therapeutics, is a consultant/advisory board member for MerckMerck and BioNTech, and owns stock in Urogen, Allogene Therapeutics, Neogene Therapeutics, Kronos Bio, ByHeart, 76Bio, Vida Ventures, Ginkgo Bioworks, Doximity, and Inconovir. The other authors have no conflicts of interest to declare.

LinkOut - more resources